Cancer metabolism is a key factor in the development and progression of tumors. Abnormalities in metabolic processes, such as increased glycolysis and enhanced anabolic pathways, contribute to tumor growth, spread, resistance to treatment, and the presence of cancer stem cells. The success of drugs that target specific metabolic enzymes showcases the potential of targeting metabolism in cancer therapy. Therefore, the development of compounds that inhibit cancer metabolism is crucial for advancing cancer immunotherapy.
Fig.1 The metabolism in normal cells and cancer cells.1
Creative Biolabs provides a cost-effective metabolism inhibitor development service for advancing the development of cancer immunotherapy. Incorporating medicinal chemistry and structural biology, our service is capable of discovering and developing cancer metabolism inhibitors that are highly specific and effective.
Throughout the development process, screening the appropriate target is a critical step. With our diverse compound library and advanced prediction and analysis techniques, we are able to assist customers in identifying potential target compounds. Meanwhile, our state-of-the-art instruments enable high-throughput screening and identification for large-scale target screening. Additionally, we provide fully constructed cell models and animal models for the in vivo efficacy evaluation to screen the potent cancer metabolism inhibitors. Noteworthy, various factors such as intracellular enzyme concentration affect the development of inhibitors. Our experienced research team is dedicated to providing customized solutions to overcome any obstacles and minimize the impact.
Fig.2 The workflow of our metabolism inhibitor development service for cancer immunotherapy.
To develop effective cancer metabolism inhibitors, it is crucial to select specific molecular targets. Here we deliver various services and numerous targets for specific cancer metabolism pathways to aid customers in inhibitor development designing:
| Our Services | Targets |
|---|---|
| TYMS, DHFR, RNR, SHMT1, SHMT2, PHGDH, MTHFD2, IMPDH, DHODH, etc. | |
| GLUT1, GLUT2, GLUT3, GLUT4, HK2, ENO2, PKM2, LDHA, LDHB, MCT1, MCT4, etc. | |
| GLS1, GLS2, PPAT, PFAS, GMPS, CAD, CTPS, NADSYN, glutaminase, PYCR, etc. | |
| CPT1A, ACC1, ACC2, ACLY, ACSS2, SCD1, etc. | |
| COX-2, Indoleamine dioxygenase, IDO1, etc. |
Metabolic inhibitors to target cancer cells are a promising approach to impede tumor growth and metastasis by disrupting their unique metabolic processes. As an industrial-leading company, Creative Biolabs integrates cutting-edge technologies to develop the metabolism inhibitor development service platform for cancer immunotherapy progress. Please feel free to get in touch with us for more details.
Reference
For Research Use Only | Not For Clinical Use
Download our brochure